DarDoc Research

GLP-1 Trial & Approval Tracker

All studies

OASIS 4 trial results

Adults with overweight or obesity without diabetes.

Wegovy tablets
Phase
Phase 3b
Follow-up
64 weeks
Randomised
307
Sponsor
Novo Nordisk
Publication
New England Journal of Medicine · 2025

Double-blind, placebo-controlled. Treatment-policy analysis.

Mean body weight change at 64 weeks
  • Oral semaglutide 25 mg−13.6%
  • Placebo−2.2%
Mean body weight change at 64 weeks
Trial armResult
Oral semaglutide 25 mg−13.6%
Placebo−2.2%
Participants who reported gastrointestinal events
Trial armResult
Oral semaglutide 25 mg74.0%
Placebo42.2%

Safety. The paper reported more gastrointestinal events with oral semaglutide than with placebo.